Facebook link Linked In link You Tube link

Cancer Immunity & Immunotherapy

Organized in collaboration with the Society for Immunotherapy of Cancer (SITC)

FOCIS logo NO-WEB

sitclogo

Cancer Immunity & Immunotherapy

Wednesday, June 14 at FOCIS 2017 
Hilton Chicago Hotel
Chicago, Illinois

You may add Cancer Immunity & Immunotherapy to your FOCIS 2017 registration or attend the course only. Please choose the appropriate link below.

FOCIS 2017 & Course          Course Only

 


Purpose

The purpose of this course is to review tumor immunology as the scientific foundation for the current practice of cancer immunotherapy, emphasizing fundamental principles, recent clinical advances, current limitations, and near-term opportunities for further accelerating clinical progress.

Target Audience

This course is designed for translational researchers and scientists, practicing clinicians, trainees, and indviduals in biotechnology and pharmaceutical companies interested in immuno-oncology and the development of immunotherapies for cancer.

Course Objectives

Completion of this course, will allow participants to:

  • Describe mechanisms of the immune response against cancer cells and how these responses are regulated during cancer development and progression.
  • Describe the principles underlying chimeric antigen receptor-transduced T cells (CAR-T cells) and T cell receptor (TCR)-transduced T cells and their efficacy in the treatment of leukemias and other cancers.
  • Appreciate the potential opportunities and limitations of utilizing CAR-T cells for treating solid tumors and understand the development of second generation CARs.
  • Understand the biology of immune checkpoint pathways and checkpoint blockade therapy for solid tumors, the development of biomarkers to predict therapeutic responses, and the potential for combination therapies.
  • Describe the unique adverse event profile associated with immune checkpoint blockade and CAR-T cell therapy, and clinical strategies for managing those immune-related toxicities.
  • Understand the potential of emerging strategies for cancer immonotherapy.

Course Agenda 

Wednesday, June 14
8:00am - 9:00am The Mechanistic Basis of Cancer Immunotherapy
9:00am - 9:40am Manipulating the Tumor Environment (DCs, Tregs, others)
9:40am - 10:00am Break
10:00am-10:40am CAR-T Cell Therapy: Principles and Current Practices
10:40am - 11:20am CAR-T Cell Therapy: Next Generation CARs Toxicities, Challenges and Prospects
11:20am-12:00pm T-Cell Receptor Transduced T Cells
12:00pm - 1:00pm Lunch with Faculty
1:00pm - 2:00pm Checkpoint Blockade Therapy: Current Status & Biomarkers
2:00pm - 2:40pm Next Generation Checkpoint and Combination Therapies
2:40pm - 3:20pm Focus on Engineered Antibodies (BiTE/other)
3:20pm - 4:00pm Immune-Related Toxicity: Mechanisms and Management
4:00pm - 4:20pm Break
4:20pm - 5:00pm Vaccination Strategies, Identification of Neoantigens
5:00pm - 5:30pm Future Prospects and Challenges in Cancer Immunotherapy
5:30pm - 6:00pm Panel Discussion
   
Continuing Medical Education (CME)
FOCIS will not offer CME credit for any course or session at FOCIS 2017. Certificates of attendance will be available upon request.
Share